The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK MARKET TALK ROUNDUP: BROKERS COMMENTS

Mon, 02nd Aug 2010 14:21

Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 1321 GMT [Dow Jones] Ambrian initiates coverage of Vectura Group (VEC.LN) with a buy rating and fair value of 98p. Analyst Chris Redhead says the drug maker is significantly undervalued. A program with Novartis (NOVN.VX) could bring the companies a significant share of the $9 billion-a-year market for medicines for chronic obstructive pulmonary disease, or smoker's lung, and a clear route to market exists in Europe for Vectura's generic version of GlaxoSmithKline (GSK.LN) asthma blockbuster even if it doesn't in the U.S., he says. It also has other products ready for partnering with a big drug maker, Redhead adds. Shares flat at 44p (jason.douglas@dowjones.com). 1315 GMT [Dow Jones] Collins Stewart lowers Keller Group (KLR.LN) target price to 644p from 670p. The company's 1H results are "very weak," but this was well flagged by the profit warning in May. Most of the damage was done by the US operations, in which EBIT swung to GBP1M loss from a GBP19M profit, with revenues down by a quarter, the brokerage says. Still, Collins Stewart says the outlook is starting to improve, with the company seeing orders grow at the group level for each month since December 2009. Buy rating. Shares +4.7% at 575p. (ishaq.siddiqi@dowjones.com) 0934 GMT [Dow Jones] Deutsche Bank cuts Anglo American (AAL.LN) price target to 3450p from 3520p following the company's 1H '10 results. Earnings are marginally ahead of expectations but essentially, this is a result of strong outperformance in iron ore. Operationally, Met coal, thermal coal, nickel and copper are below expectations. Deutsche also notes further bad news regarding the Minas Rio project. The project has been delayed and Anglo is not able to clearly forecast the capex level. Deutsche thinks the delay will be least nine months and as a result, capex is up $750M. Keeps at buy. Shares are +3.5% at 2612p. (andrea.tryphonides@dowjones.com) 0744 GMT [Dow Jones] Hammerson (HMSO.LN) "is doing all the right things" says an analyst at Evolution Securities. The analyst notes Hammerson is the only major real estate investment trust to increase its dividend year-on-year in 1H. "We support this strongly," says the analyst. The analyst says the company is also the only major REIT to have changed its corporate structure in the first half. This follows last year's rights issue. "Lower gearing, less development risk and greater asset churn are the manifestations." Add rating, 420p target. Shares +4% at 404p. (anita.likus@dowjones.com) 0735 GMT [Dow Jones] Hammerson's (HMSO.LN) results are in line with expectations, says KBC Peel Hunt. Hammerson has been one of the most active recyclers of capital amongst its peer group in the last 18 months, making over GBP700M of disposals, while acquisitions have totaled about GBP100M,says KBC Peel. It notes the company is bullish on the City office market, based on market expectations of a sustained recovery in rental levels over coming years. Buy recommendation. Shares +4.2% at 404.7p. (andrea.tryphonides@dowjones.com) 0733 GMT [Dow Jones] WS Atkins' (ATK.LN) 1Q interim management statement is in-line yet cautious says Execution Noble. Unsurprisingly, weakness has been evident in education while the group's UK highways and international activities appear steady. The acquisition of PBSJ, is a strategically important move, says Execution. It represents an opportunity to diversify the group's revenues, given budgetary headwinds, says Execution. The key issues are on the business fit as well as updated prospects for the UK business. Hold rating. Shares +2.7% at 733p. (andrea.tryphonides@dowjones.com) 0657 GMT [Dow Jones] Intertek Group's (ITRK.LN) 1H results are stronger than expected at a revenue level but in line at EBITA level, says an analyst. Says the revenue beat is driven by robust organic growth. Says for '10, the company expects organic revenue growth in mid-single digits and for margins to be flat. As a result, the analyst does not expect significant upgrades to consensus estimates. Shares closed on Friday at 1577p. (andrea.tryphonides@dowjones.com) 0657 GMT [Dow Jones] Intertek's (ITRK.LN) 1H results are stronger than expected at revenue level, but in line at Ebita level, says analyst. In terms of the outlook, the company now expects organic growth in mid single digits and flat margins. But this is "not enough to push consensus materially higher," the analyst adds. Intertek shares closed at 1577p Friday. (LEV) 0648 GMT [Dow Jones] Senior's (SNR.LN) interim pretax profit is ahead of expectations says a trader. FY adjusted EPS is lifted by 4% to 10.7p notes the trader. The trader sees potential for further upgrades during the 2H and says the shares look attractive particularly as the outlook for civil aerospace continues to improve. Shares closed Friday at 127.5p.(andrea.tryphonides@dowjones.com) 0638 GMT [Dow Jones] Randgold Resources (RRS.LN) will likely open weaker Monday, after lowering its production guidance from its Loulo gold mine says a trader. Says Randgold is expecting Loulo's output for '10 to be within 5% and 10% of its original forecast of 400,000 ounces. Shares closed on Friday at 5730p. (andrea.tryphonides@dowjones.com) 0620 GMT [Dow Jones] Citigroup raises British American Tobacco (BATS.LN) target to 2570p from 2460p after its 1H '10 adjusted EPS beats consensus by 3%. Says the company's 1H results are stronger than expected in all regions apart from Eastern Europe. Lifts '10 EPS forecast to 178.4p from 175.4p and '11 to 195.2p from 191.9p. Says the global slowdown has impacted cigarette volumes much more than the market expected but this has been made up for by very large price increases. Notes that British American is seeing signs of improving volumes, especially in Russia. Maintains buy rating. Shares closed Friday at 2194p. (andrea.tryphonides@dowjones.com) 0615 GMT [Dow Jones] Citigroup nudges up British Airways (BAY.LN) price target to 295p from 280p, based on 100% profitability of its joint-venture with American Airlines going ahead and on updated combined BA/Iberia Lineas Aereas de Espana (IBLA.MC) valuation. Also, following stronger than expected 1Q results, raises '11E operating profit to GBP437M from GBP245M. Lifts '11 EPS forecast to 8.9p from a loss per share of 2.0p, and raises '12 EPS forecast to 27.3p from 22.1p. Keeps BA at buy. Shares closed on Friday at 219.6p. (andrea.tryphonides@dowjones.com) Contact us in London. +44-20-7842-9288 Markettalk.eu@dowjones.com (END) Dow Jones Newswires August 02, 2010 09:21 ET (13:21 GMT)
More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.